Brief: Ocugen Announces Positive Data And Safety Monitoring Board Review And Initiation Of Enrollment In Medium Dose For Ocu410st—A Modifier Gene Therapy—In Gardian Study For Stargardt Disease

Ocugen

01/04/2024 23:26

April 1 (Reuters) - Ocugen Inc  OCGN.O :
    * OCUGEN ANNOUNCES POSITIVE DATA AND SAFETY MONITORING BOARD
REVIEW AND INITIATION OF ENROLLMENT IN MEDIUM DOSE FOR
OCU410ST—A MODIFIER GENE THERAPY—IN GARDIAN STUDY FOR STARGARDT
DISEASE
    * OCUGEN INC - ESTABLISHED LOW DOSE AS SAFE AND TOLERABLE
DOSE IN
CURRENT OCU410ST CLINICAL TRIAL
    * OCUGEN INC - DSMB DETERMINATION TO PROCEED WITH MEDIUM
DOSE
COHORT DOSING

Source text for Eikon:  ID:nGNX8xj9v4 
Further company coverage:  OCGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))